Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs : a population-based study
| Errataetall: |
CommentIn: Ann Rheum Dis. 2021 Jun;80(6):e96. - PMID 32632030 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 7 vom: 17. Juli, Seite 986-988 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvarani, Carlo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.06.2020 Date Revised 05.07.2022 published: Print-Electronic CommentIn: Ann Rheum Dis. 2021 Jun;80(6):e96. - PMID 32632030 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-217903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310477913 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310477913 | ||
| 003 | DE-627 | ||
| 005 | 20231225140154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-217903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310477913 | ||
| 035 | |a (NLM)32467245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs |b a population-based study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.06.2020 | ||
| 500 | |a Date Revised 05.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2021 Jun;80(6):e96. - PMID 32632030 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a epidemiology | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Pyrroles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a guselkumab |2 NLM | |
| 650 | 7 | |a 089658A12D |2 NLM | |
| 650 | 7 | |a canakinumab |2 NLM | |
| 650 | 7 | |a 37CQ2C7X93 |2 NLM | |
| 650 | 7 | |a brodalumab |2 NLM | |
| 650 | 7 | |a 6ZA31Y954Z |2 NLM | |
| 650 | 7 | |a Abatacept |2 NLM | |
| 650 | 7 | |a 7D0YB67S97 |2 NLM | |
| 650 | 7 | |a tofacitinib |2 NLM | |
| 650 | 7 | |a 87LA6FU830 |2 NLM | |
| 650 | 7 | |a ixekizumab |2 NLM | |
| 650 | 7 | |a BTY153760O |2 NLM | |
| 650 | 7 | |a secukinumab |2 NLM | |
| 650 | 7 | |a DLG4EML025 |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 700 | 1 | |a Bajocchi, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Mancuso, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Muratore, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Boiardi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Catanoso, Mariagrazia |e verfasserin |4 aut | |
| 700 | 1 | |a Pipitone, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Girolimetto, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Croci, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Cimino, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Gradellini, Federeica |e verfasserin |4 aut | |
| 700 | 1 | |a Beltrami, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lernia, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Dolci, Giovammi |e verfasserin |4 aut | |
| 700 | 1 | |a Massari, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Marata, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Costantini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgi Rossi, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 7 vom: 17. Juli, Seite 986-988 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:7 |g day:17 |g month:07 |g pages:986-988 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-217903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 7 |b 17 |c 07 |h 986-988 | ||